Clarivate Q3 2026 earnings

CLVT · 2026-11-03 08:04 BMO ET · 8-K on SEC

Adjusted EBITDA margin improved to 43.2% as organic recurring revenue growth accelerated and the LS&H segment was divested.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$567.9M-8.9%-3.4%Ex. 99.1, income statement
EPS (GAAP)-$0.13-225%+9.5%Ex. 99.1, income statement
EPS (adjusted)$0.21+16.7%+10.5%Ex. 99.1, income statement
Net income-$80.8M-185%+70%Ex. 99.1, income statement
Adj. EBITDA$245.3M-2.8%-0.4%Ex. 99.1, income statement
Adj. EBITDA margin43.2%+2.7 pp+1.1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Academia & Government$338.3M+0.7%59.6%Subscription revenue up 1.5% organically
Intellectual Property$105.8M+0.5%18.6%Re-occurring revenue up 0.7% organically
Life Sciences & Healthcare$37.5M-51.6%6.6%Divested Oct 6, 2026
Discontinued Operations$481.6M-9.2%84.8%Excluding LS&H

Margins and costs

  • Gross margin 23.6% (prior 23.6%, change 0.0 pp)
  • Operating expenses $441.5M (+8.9% YoY)
  • One-offs in the quarter $62.2M LS&H goodwill impairment; $10.1M loss on classification as held for sale; $4.9M restructuring costs
  • Effective tax rate 7.7% (prior-year 3.8%, year-to-date 27.1%)
  • Non-GAAP bridge Adds back amortization, share-based comp, impairments, restructuring, transaction costs, FX and other items; excludes LS&H divestiture impact.

KPIs

MetricActualPrior quarterPrior yearChange
Organic ACV1.8%1.5%N/A+0.3 pp
Organic recurring revenue growth0.9%0.7%N/A+0.2 pp
Organic subscription growth1.5%0.7%N/A+0.8 pp

Guidance

MetricGuidePrior guideChange
Revenues$490M to $510M$2.30B to $2.42BLowered guidance to reflect LS&H divestiture
Adjusted EBITDA$215M to $235M$980M to $1.04BLowered guidance to reflect LS&H divestiture
Adjusted EBITDA Margin44.0% to 46.0%42.0% to 43.5%Raised margin outlook
Adjusted Diluted EPS$0.14 to $0.18$0.70 to $0.80Lowered EPS outlook to reflect LS&H divestiture
Free Cash Flow$85M to $105M$365M to $435MLowered FCF outlook to reflect LS&H divestiture

What drove it

  • Revenue story Total revenue declined 8.9% YoY to $567.9M, driven by the divestiture of the LS&H segment. Excluding LS&H, continuing operations revenue was $481.6M, down 9.2% YoY, with organic revenue up 0.4% as subscription growth offset transactional declines.
  • EPS story GAAP EPS loss widened to -$0.13 due to a $62.2M LS&H goodwill impairment and higher tax expense. Adjusted EPS improved to $0.21, driven by higher adjusted net income and lower share count.
  • One-off check $62.2M LS&H goodwill impairment and $10.1M loss on classification as held for sale (non-cash).

The good

  • Adjusted EBITDA margin expanded to 43.2%
  • Organic recurring revenue growth accelerated to 0.9%
  • Organic subscription growth returned to 1.5%
  • Organic ACV growth improved to 1.8%

The bad

  • Total revenue declined 8.9% YoY
  • Organic transactional revenue declined 12.4%
  • Adjusted EBITDA declined 2.8% YoY

The ugly

  • none

Open questions

  • The impact of the LS&H divestiture on the company's long-term growth profile and revenue mix.
  • The specific drivers of the continued decline in organic transactional revenues.
Full release

Clarivate (CLVT) earnings release, November 3, 2026

Clarivate Plc (CLVT) · Form 8-K, Item 2.02 · Filed · SEC filing

1

Clarivate Reports

Third

Quarter

2026

Results, Delivering Clear Path to Value Creation — Improved recurring organic revenue growth driven by portfolio transformation and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare segment — London, UK --

November 3, 2026

Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the third quarter ended

September 30,

2026.

Executive Commentary

Matti Shem Tov, Chief Executive Officer:

“Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment. We also achieved a major milestone with the early close of the Life Sciences & Healthcare segment divestiture, positioning us for enhanced value creation in our two market-leading segments, Academia & Government and Intellectual Property. The growing commercial traction and customer validation from our AI-led innovation within A&G and IP give us confidence in our ability to deliver on our commitments of accelerating sustained organic growth, expanding free cash flow and reducing leverage.”

Michael Easton, Executive Vice President and Chief Financial Officer:

“We are seeing the benefits of disciplined execution across the business, with improving growth trends, strong margins and continued free cash flow generation. Our focus remains on translating organic growth into sustainable earnings and free cash flow, while maintaining a disciplined approach to capital allocation. Looking ahead, we are well positioned to further strengthen our financial profile and enhance our financial flexibility.”

Third

Quarter

2026

Results

Total revenues were

$567.9 million, including the Life Sciences & Healthcare segment (“LS&H”), which was divested on October 6, 2026, compared to total revenues of

$623.1 million for the third quarter of 2025, primarily due to inorganic disposals. Excluding LS&H, which is now presented as discontinued operations, total revenues were

$481.6 million, compared to total revenues of

$530.3 million for the third quarter of

2025, primarily due to inorganic disposals.

Organic revenues for continuing operations increased

0.4% as organic subscription growth of

1.5% and organic re-occurring growth of

0.7% was partially offset by lower organic transactional revenues.

Organic ACV for continuing operations grew

1.8% compared to

September 30, 2025, reflecting continued progress toward a more sustainable, subscription-led revenue base.

Net loss, including LS&H, was

$80.8 million, or

$0.13 per diluted share, compared to a net loss of

$28.3 million, or

$0.04 per diluted share, for the third quarter of

2025, driven by a

$62.2 million non-cash LS&H goodwill impairment charge. Adjusted net income, including LS&H, was

$136.0 million, or

$0.21 per diluted share, compared to

$119.3 million, or

$0.18 per diluted share, for the third quarter of

2025. Adjusted EBITDA, including LS&H, was

$245.3 million, compared to Adjusted EBITDA of

$252.4 million for the third quarter of

2025.

First Nine Months

2026

Results

Total revenues were

$1,740.7 million, including the LS&H segment, compared to total revenues of

$1,838.2 million, primarily due to inorganic disposals. Excluding the LS&H segment, which is now presented as discontinued operations, total revenues were

$1,472.4 million, compared to total revenues of

$1,546.7 million for the first nine months of

2025, primarily due to inorganic disposals.

Organic revenues for continuing operations increased

0.1%, as a

0.9% increase in organic recurring revenues

(subscription and re-occurring) was offset by lower organic transactional revenues.²

Net loss, including LS&H, was

$389.6 million, or

$0.61 per diluted share, compared to a net loss of

$204.2 million, or

$0.30 per diluted share, for the first nine months of

2025, driven by a

$283.9 million non-cash LS&H goodwill impairment charge. Adjusted net income, including LS&H, was

$378.4 million, or

$0.59 per diluted share, compared to

$338.4 million, or

$0.49 per diluted share, for the first nine months of

2025. Adjusted

EBITDA, including LS&H, was

$733.7 million, compared to Adjusted EBITDA of

$747.2 million for the first nine months of

2025.

Clarivate, including LS&H, generated

$399.0 million of operating cash flow and

$233.1 million of free cash flow during the first nine months of

2026.

Selected Financial Information

Third

Quarter

2026

Continuing Operations Commentary

Subscription revenues increased

$2.4 million, or

0.7%, to

$338.3 million. Organic subscription revenues increased

1.5%, primarily due to new sales and pricing actions.

Re-occurring revenues increased

$0.5 million, or

0.5%, to

$105.8 million. Organic re-occurring revenues increased

0.7%, primarily due to higher IP volumes.

Recurring revenues, which consist of subscription and re-occurring revenues, increased

1.3% organically, or

$5.7 million.

Transactional revenues decreased

$51.6 million to

$37.5 million, primarily due to product group wind-downs within A&G.

On an organic basis, the decline was

12.4%, or

$3.9 million, primarily due to lower activity across both segments, driven in part by customer migration to higher margin subscription products as we focus on our recurring revenues.

Balance Sheet and Cash Flow

As of

September 30, 2026, cash and cash equivalents of

$257.0 million decreased

$72.2 million compared to

December 31, 2025.

Total debt outstanding was

$4,176.1 million as of

September 30, 2026, a decrease of

$293.8 million compared to the prior year, driven by a $100.0 million accelerated debt repayment in January 2026 resulting in the full³.demption of the senior secured notes due November 2026, as well as the retirement of

$192.6 million aggregate principal of the senior secured notes due 2028 and senior notes due 2029 through a series of debt repurchases at an approximate 5% discount to par.

Net cash provided by operating activities including discontinued operations for the first nine months of

2026 was

$399.0 million compared to

$468.6 million in the prior year period. Free cash flow including discontinued operations for the first nine months of

2026 was

$233.1 million compared to

$276.1 million in the prior year period.

On October 6, 2026 the company completed the sale of the LS&H segment for net cash proceeds of

$488.4 million.

Updates

2026 outlook excluding discontinued operations (forward-looking statement)

The full year 2026 outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.

The Q4 2026 outlook presented below is provided in connection with the completion of the LS&H divestiture and also assumes no further acquisitions, divestitures, or unanticipated events.

Notes to press release

(1)

Non-GAAP measure. Please see “Reconciliations to Certain Non-GAAP Measures” in this release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this press release.

(2)

Adjusted diluted EPS for the full year and Q4

2026 outlooks are calculated based on approximately

646 million fully diluted adjusted weighted average ordinary shares outstanding. The full year 2026 outlook includes results from discontinued operations for the nine months ended September 30, 2026 and excludes results from discontinued operations for the three months ended December 31, 2026.

(3)

Free cash flow includes results from discontinued operations for the nine months ended September 30, 2026 and excludes results from discontinued operations for the three months ended December 31, 2026.

Conference Call and Webcast

Clarivate will host a conference call and webcast today to review the results for the third quarter at 8:30 a.m.

Eastern Time. The webcast is open to all interested parties and may include forward-looking information.

The live webcast of the earnings call will be accessible through the investor relations section of the Company’s website. To join the webcast please visit https://events.q4inc.com/attendee/388781202.

Interested parties may access the live audio broadcast. U.S. participants may call 833-461-5787; international participants may call +1 585-542-9983 (long-distance charges will apply). The conference ID number is 388 781

202.

A replay of the webcast will also be available on https://ir.clarivate.com beginning two hours after the conclusion of the live call and will remain available for one year.

Use of Non-GAAP Financial Measures

This release contains financial measures that have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net income,

Adjusted diluted EPS, and Free cash flow. Non-GAAP financial measures are not recognized terms under GAAP, are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with⁴

GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.

We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating performance of our business, to assess performance for employee compensation purposes, and to decide how to allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. Further, these measures can be useful in evaluating our performance against our peer companies because we believe they provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.

Financial statements

Income Statement

Three Months Ended September 30, — Selected Financial Information (In millions, except percentages and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Change – $Change – %Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Change – $Change – %
Revenues, including discontinued operations567.9623.1-55.2-8.9%1,740.71,838.2-97.5-5.3%
Revenues, continuing operations481.6530.3-48.7-9.2%1,472.41,546.7-74.3-4.8%
Net income (loss)-80.8-28.3-52.5N/M-389.6-204.2-185.4N/M
Adjusted net income(1)136119.316.714.0%378.4338.44011.8%
Adjusted EBITDA, including discontinued operations(1)245.3252.4-7.1-2.8%733.7747.2-13.5-1.8%
Adjusted EBITDA, continuing operations(1)218.2222.2-4-1.8%645.6645.7-0.1–%
Diluted EPS, continuing operations-0.04-0.040–%-0.19-0.310.12-38.7%
Diluted EPS, discontinued operations-0.090-0.09N/M-0.420.01-0.43N/M
Diluted EPS, including discontinued operations-0.13-0.04-0.09N/M-0.61-0.3-0.31N/M
Adjusted diluted EPS(1)0.210.180.0316.7%0.590.490.120.4%
Net cash provided by operating activities165.6181.1-15.5-8.6%399468.6-69.6-14.9%
Free cash flow(1)110.2115.5-5.3-4.6%233.1276.1-43-15.6%

Income Statement

Three Months Ended September 30, — Unaudited (In millions, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues481.6530.31,472.41,546.7
Operating expenses:
Cost of revenues139178.5442.4511.3
Selling, general and administrative costs134.6145.7447.3453.2
Depreciation and amortization162.3168.6484.7499.2
Restructuring costs4.57.924.934.3
Other operating expense (income), net1.1-16.3-8.433.6
Total operating expenses441.5484.41,390.91,531.6
Operating income (loss)40.145.981.515.1
Interest expense, net6168.5180.4199.4
Income (loss) from continuing operations before income taxes-20.9-22.6-98.9-184.3
Provision (benefit) for income taxes5.52.323.429
Income (loss) from continuing operations, net of taxes-26.4-24.9-122.3-213.3
Income (loss) from discontinued operations, net of taxes-54.4-3.4-267.39.1
Net income (loss)-80.8-28.3-389.6-204.2
Basic earnings (loss) per share:
Continuing operations-0.04-0.04-0.19-0.31
Discontinued operations-0.09-0.420.01
Basic earnings (loss) per share-0.13-0.04-0.61-0.3
Diluted earnings (loss) per share:
Continuing operations-0.04-0.04-0.19-0.31
Discontinued operations-0.09-0.420.01
Diluted earnings (loss) per share-0.13-0.04-0.61-0.3
Weighted average shares used to compute earnings per share:
Basic639.7668.3639.9679.7
Diluted639.7668.3639.9679.7

Income Statement

Three Months Ended September 30, — margin for the same periods: (In millions, except percentages)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)-80.8-28.3-389.6-204.2
Provision (benefit) for income taxes7.73.827.134.9
Depreciation and amortization162.3191.8532568.1
Interest expense, net6168.5180.4199.4
Share-based compensation expense10.81640.545.6
Goodwill and intangible asset impairments62.2283.9
Loss on classification as held for sale10.110.1
Restructuring costs4.911.92945.9
Transaction related costs8.14.126.518.5
Other(1)-1-15.4-6.239
Adjusted EBITDA, including discontinued operations245.3252.4733.7747.2
Net income (loss) margin-14.9%-4.5%-22.6%-11.1%
Adjusted EBITDA margin43.2%40.5%42.1%40.6%

Income Statement

Three Months Ended September 30, — periods: (In millions, except per share amounts)

Three Months Ended September 30, – 2026 – AmountThree Months Ended September 30, – 2026 – Per ShareThree Months Ended September 30, – 2025 – AmountThree Months Ended September 30, – 2025 – Per Share
Net income (loss) and Diluted EPS-80.8-0.13-28.3-0.04
Amortization related to acquired intangible assets122.60.19136.70.2
Share-based compensation expense10.80.02160.02
Goodwill and intangible asset impairments62.20.1
Loss on classification as held for sale10.10.02
Restructuring costs4.90.0111.90.02
Transaction related costs8.10.014.10.01
Other(1)0.7-0.01-14-0.02
Income tax impact of related adjustments-2.6-7.1-0.01
Adjusted net income and Adjusted diluted EPS1360.21119.30.18
Adjusted weighted average ordinary shares, diluted643.6675.5

Income Statement

Year Ending December 31, 2026 (Forecasted) — income (loss) margin for the same period: (in millions)

Year Ending December 31, 2026 (Forecasted) – LowYear Ending December 31, 2026 (Forecasted) – High
Net income (loss)-154-144
Provision (benefit) for income taxes4545
Depreciation and amortization650650
Interest expense, net225230
Share-based compensation expense4550
Restructuring costs(1)3030
Transaction related costs3535
Other-11-11
Adjusted EBITDA865885
Net income (loss) margin-7.8%-7.3%
Adjusted EBITDA margin43.0%45.0%

Income Statement

Year Ending December 31, 2026 (Forecasted) — per share for the same period:

Year Ending December 31, 2026 (Forecasted) – LowYear Ending December 31, 2026 (Forecasted) – High
Net income (loss) per share-0.65-0.62
Amortization related to acquired intangible assets0.80.8
Share-based compensation expense0.070.08
Goodwill and intangible asset impairments0.460.46
Restructuring costs(1)0.050.05
Transaction related costs0.050.05
Other-0.02-0.02
Income tax impact of related adjustments-0.03-0.03
Adjusted diluted EPS0.730.77
Adjusted weighted average ordinary shares, diluted~650 million

Balance Sheet

September 30, 2026 — Unaudited (in millions)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents, including restricted cash257329.2
Accounts receivable, net747.4696.8
Prepaid expenses95.779.2
Other current assets61.662
Current assets held for sale70.6142.8
Total current assets1,232.31,310
Property and equipment, net44.652
Other intangible assets, net7,155.57,515.9
Goodwill1,088.81,088.9
Other non-current assets109.359.9
Deferred income taxes19.416.1
Operating lease right-of-use assets38.745.4
Non-current assets held for sale679.7981.2
Total assets10,368.311,069.4
Current liabilities:
Accounts payable117.2138.8
Accrued compensation87.3114.6
Accrued expenses and other current liabilities276.3260
Current portion of deferred revenues761.3737.4
Current portion of operating lease liability16.317.8
Current portion of long-term debt1.6101.5
Current liabilities held for sale144.5198.7
Total current liabilities1,404.51,568.8
Long-term debt4,136.84,321.5
Other non-current liabilities72.681.1
Deferred income taxes195201.8
Operating lease liabilities29.237.3
Non-current liabilities held for sale15.816
Total liabilities5,853.96,226.5
Shareholders' equity:
Ordinary Shares, no par value; unlimited shares authorized; 639.9 and 640.7 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively12,825.812,810.6
Accumulated other comprehensive loss-407.2-453.1
Accumulated deficit-7,904.2-7,514.6
Total shareholders' equity4,514.44,842.9
Total liabilities and shareholders' equity10,368.311,069.4

Cash Flow

Full Year 2026 Outlook — also assumes no further acquisitions, divestitures, or unanticipated events.

Full Year 2026 OutlookQ4 2026 Outlook
ACV Organic Growth1.75% to 2.25%1.75% to 2.25%
Recurring Organic Revenue Growth1.00% to 1.50%2.00% to 2.50%
Revenues$1.965B to $1.985B$490M to $510M
Adjusted EBITDA(1)$0.865B to $0.885B$215M to $235M
Adjusted EBITDA Margin(1)43.0% to 45.0%44.0% to 46.0%
Adjusted Diluted EPS(1)(2)$0.73 to $0.77$0.14 to $0.18
Free Cash Flow(1)(3)$320M to $340M$85M to $105M

Cash Flow

Nine Months Ended September 30, — Unaudited (in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash Flows From Operating Activities
Net income (loss)-389.6-204.2
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization532568.1
Share-based compensation40.245.4
Goodwill and intangible asset impairments283.9
Loss on classification as held for sale10.1
Deferred income taxes-9.8-11.6

Cash Flow

Three Months Ended September 30, — for the same periods: (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by operating activities165.6181.1399468.6
Capital expenditures-55.4-65.6-165.9-192.5
Free cash flow110.2115.5233.1276.1

Cash Flow

Year Ending December 31, 2026 (Forecasted) — provided by operating activities for the same period: (in millions)

Year Ending December 31, 2026 (Forecasted) – LowYear Ending December 31, 2026 (Forecasted) – High
Net cash provided by operating activities550570
Capital expenditures-230-230
Free cash flow320340

Forward-Looking Statements

This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of

1995. These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, any future strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our Life Sciences &... (true business, and any related cost savings or other benefits, our results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, our prospects, growth, strategies and shareholder value, the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,”

“estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government and Intellectual Property. For more information, please visit www.clarivate.com.⁵

Condensed Consolidated Balance Sheets – Unaudited⁶

Condensed Consolidated Statements of Operations – Unaudited⁷

Condensed Consolidated Statements of Cash Flows – Unaudited⁸

Supplemental Revenues Information

Annualized contract value (“ACV”), at any point in time, represents the annualized value of all active customer subscription-based license agreements for the next 12 months, assuming those coming up for renewal during the measurement period are renewed at their current price level. Our organic ACV grew

1.8% compared to

September 30, 2025, primarily driven by improved product pricing. Our total ACV for

September 30, 2026, compared to

September 30, 2025, increased

3.6%, primarily due to improved product pricing and FX movements.

The following tables present our revenues by type and segment, as well as the components driving the changes between periods.

Revenues by transaction type

Revenues by segment⁹

Reconciliations to Certain Non-GAAP Measures

Adjusted EBITDA and Adjusted EBITDA margin

Adjusted EBITDA represents

Net income (loss) before the

Provision (benefit) for income taxes,

Depreciation and amortization, and

Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in

Net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Net income (loss) margin is calculated by dividing

Net income (loss) by Revenues. Adjusted

EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

The following table presents our calculation of

Adjusted EBITDA and

Adjusted EBITDA margin for the three and nine months ended September 30, 2026 and

2025 and reconciles these non-GAAP measures to our

Income

(loss) from continuing operations, net of taxes and

Income (loss) from continuing operations margin for the same periods:

(1)

Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances, the impact of initiatives to reduce our cost structure related to the LS&H divestiture, and other items that do not reflect our ongoing operating performance.¹⁰

The following table presents our calculation of

Adjusted EBITDA, including discontinued operations and

Adjusted EBITDA margin for the three and nine months ended September 30, 2026 and

2025 and reconciles these non-GAAP measures to our Net i ncome (loss) and Net income (loss) margin for the same periods:

(1)

Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance.

Adjusted net income and Adjusted diluted EPS

Adjusted net income represents Net income (loss), adjusted to exclude amortization related to acquired intangible assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign... (truncated)or the period that we do not consider indicative of our ongoing operating performance and the associated income tax impact of such adjustments.

Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares.

The Adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive.¹¹

The following tables present our calculation of Adjusted net income including discontinued operations and

Adjusted diluted EPS including discontinued operations for the three and nine months ended September 30, 2026 and

2025 and reconciles these non-GAAP measures to our Net income (loss) and diluted EPS for the same periods:

(1)

Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance.

(1)

Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance.

Free cash flow

Free cash flow represents Net cash provided by operating activities less Capital expenditures. The following table presents our calculation of Free cash flow including discontinued operations for the three and nine months ended

September 30, 2026 and

2025 and reconciles this non-GAAP measure to Net cash provided by operating activities for the same periods:¹²

Reconciliations to Certain Non-GAAP Measures - 2026 Outlook

Adjusted EBITDA and Adjusted EBITDA margin

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for continuing operations for the 2026 outlook and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the same period:

(1)

Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.

Adjusted diluted EPS

The following table presents our calculation of Adjusted diluted EPS for the 2026 outlook, including the impact of discontinued operations for the first nine months, and reconciles this non-GAAP measure to our

Net income (loss) per share for the same period:

(1)

Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.¹³

Free cash flow

The following table presents our calculation of

Free cash flow for the

2026 outlook, including the impact of discontinued operations for the first nine months, and reconciles this non-GAAP measure to our Net cash provided by operating activities for the same period:

Media Contact:

Amy Bourke-Waite, Senior Director, Communications & Brand newsroom@clarivate.com

Investor Relations Contact:

Mark Donohue, Vice President, Investor Relations investor.relations@clarivate.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Clarivate earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.